137643-14-2

Upstream product

• 88-65-3 2-bromobenzoic-acid 
• 129688-76-2 2-[(4-Bromo-2-fluorophenyl)methyl]-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-1,3-dioxo-4-isoquinolineacetic Acid 1,1-Dimethylethyl Ester 
• 129688-70-6 2-[(4-Bromo-2-fluorophenyl)methyl]-1,2,3,4-tetrahydro-1,3-dioxo-4-isoquinoline-carboxylic Acid Methyl Ester 
• 129689-07-2 (2-Carboxyphenyl)propanedioic Acid Dimethyl Ester 
• 137643-17-5 2-(2-Chlorocarbonyl-phenyl)-malonic acid dimethyl ester 
• 112734-22-2 4-bromo-2-fluorobenzylamine 
• 129688-82-0 2-<(4-bromo-2-fluorophenyl)methyl>-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-1,3-dioxo-4-isoquinolineacetic acid 

Downstream Products

• 1027240-31-8 2-(4-Bromo-2-fluoro-benzyl)-4-(methoxycarbamoyl-methyl)-1,3-dioxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid methyl ester 
• 1026158-99-5 2-(4-Bromo-2-fluoro-benzyl)-1,3-dioxo-4-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid methyl ester 
• 137643-15-3 2-(4-Bromo-2-fluoro-benzyl)-4-ethylcarbamoylmethyl-1,3-dioxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid methyl ester 
• 1026843-11-7 2-(4-Bromo-2-fluoro-benzyl)-4-butylcarbamoylmethyl-1,3-dioxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid methyl ester 
• 129688-94-4 4-(2-amino-2-oxoethyl)-2-<(4-bromo-2-fluorophenyl)methyl>-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-1,3-dioxo-4-isoquinolineacetic acid methyl ester 
• 1027576-14-2 2-(4-Bromo-2-fluoro-benzyl)-4-methylcarbamoylmethyl-1,3-dioxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-Bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1

The high concentrations of plasma glucose formed during diabetic hyperglycemia rapidly translate into high levels of glucose in tissues where glucose uptake is independent of insulin. In these tissues that include the lens, retina, nerve, and kidney, this

N-substituted spirosuccinimide, spiropyridazine, spiroazetidine, and acetic acid aldose reductase inhibitors derived from isoquinoline-1,3- diones. 2

The isoquinoline-1,3-dione framework featured in our clinical candidate (1) and its congener was used as the template in the design of several new series of aldose reductase inhibitors (ARIs). These series included N'- substituted spirosuccinimide, spirop